Condition: Monkeypox · MPOX · Sponsor: Hospital Israelita Albert Einstein
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.
This description comes directly from the study's public registry record.
Henrique AR Fonseca, PhD · +5511968308958 · henrique.fonseca@einstein.br
Diogo Moia, PharmD · diogo.moia@einstein.br
Always discuss trial participation with your own doctor first.
| Hospital Universitário João de Barros Barreto | Belém, Pará, Brazil | Recruiting |
| Hospital Israelita Albert Einstein | São Paulo, São Paulo, Brazil | Recruiting |
| Hospital Naval Marcílio Dias | Rio de Janeiro, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05784038